Ashish M. Kamat, President of IBCG, Associated Editor at European Urology Oncology, shared Parminder Singh’s post on X, adding:
“Proud to see Roger Li pushing the field into new territory.
Combining intravesical cretostimogene with systemic nivolumab in cisplatin-ineligible MIBC, a phase 1b showing no DLTs, no new safety signals, and a 42.1% pCR rate in the per protocol population.
Congratulations, Roger. Excellent work.”
Parminder Singh, Medical Oncologist at Mayo Clinic Arizona, shared a post on X:
“Roger Li presenting the next frontier in NAC adding intravesical therapy with systemic therapy.”
Other posts about BCANTT26 on OncoDaily.